STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. J Immunother Cancer. 2023 Jan; 11(1).
View in:
PubMed
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. J Clin Oncol. 2023 Jan 20; 41(3):599-608.
View in:
PubMed
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
View in:
PubMed
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype. J Clin Invest. 2022 08 15; 132(16).
View in:
PubMed
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clin Cancer Res. 2022 08 02; 28(15):3356-3366.
View in:
PubMed
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecol Oncol Rep. 2022 Apr; 40:100974.
View in:
PubMed
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022 07 01; 40(19):2138-2147.
View in:
PubMed
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 04; 126(7):1027-1036.
View in:
PubMed
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. Int J Gynecol Cancer. 2022 01; 32(1):89-92.
View in:
PubMed
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021 12; 163(3):473-480.
View in:
PubMed
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574.
View in:
PubMed
Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
View in:
PubMed
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 05 10; 39(14):1531-1539.
View in:
PubMed
Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 05; 161(2):581-586.
View in:
PubMed
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecol Oncol. 2021 01; 160(1):227-233.
View in:
PubMed
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecol Oncol. 2021 01; 160(1):322-332.
View in:
PubMed
Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020 12; 159(3):887-898.
View in:
PubMed
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
View in:
PubMed
A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 08; 26(8):1271-1279.
View in:
PubMed
Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer. JCO Precis Oncol. 2020; 4:492-497.
View in:
PubMed
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546.
View in:
PubMed
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020 04 10; 38(11):1222-1245.
View in:
PubMed
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 Apr; 30(4):551-557.
View in:
PubMed
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 12 01; 5(12):1731-1738.
View in:
PubMed
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol Oncol. 2020 02; 156(2):488-497.
View in:
PubMed
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
View in:
PubMed
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res. 2019 10 15; 25(20):6127-6140.
View in:
PubMed
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122.
View in:
PubMed
Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
View in:
PubMed
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
View in:
PubMed
Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
View in:
PubMed
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
View in:
PubMed
Antibody-drug conjugates in gynecologic malignancies. Gynecol Oncol. 2019 06; 153(3):694-702.
View in:
PubMed
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol Cancer Ther. 2019 03; 18(3):642-655.
View in:
PubMed
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
View in:
PubMed
Technology Applications: Use of Digital Health Technology to Enable Drug Development. JCO Clin Cancer Inform. 2018 12; 2:1-12.
View in:
PubMed
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7.
View in:
PubMed
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
View in:
PubMed
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clin Cancer Res. 2018 03 15; 24(6):1389-1401.
View in:
PubMed
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017 08 28; 8(1):365.
View in:
PubMed
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 11; 27(11):2124-2130.
View in:
PubMed
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016 12 20; 34(36):4345-4353.
View in:
PubMed
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res. 2017 Mar 01; 23(5):1263-1273.
View in:
PubMed
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep. 2016 May; 18(5):29.
View in:
PubMed
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
View in:
PubMed
Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci Transl Med. 2016 Mar 09; 8(329):329ra34.
View in:
PubMed
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075.
View in:
PubMed
Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015 Aug; 16(8):876-8.
View in:
PubMed
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7.
View in:
PubMed
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
View in:
PubMed
Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 01; 32(13):1287-9.
View in:
PubMed
PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014 May; 133(2):362-9.
View in:
PubMed
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1102-7.
View in:
PubMed
Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014 Feb 15; 74(4):1141-52.
View in:
PubMed
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A. 2013 Oct 15; 110(42):17041-6.
View in:
PubMed
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013 Nov; 131(2):352-6.
View in:
PubMed
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
View in:
PubMed
Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep. 2011 Dec; 13(6):450-8.
View in:
PubMed
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol. 2011 Oct; 123(1):5-12.
View in:
PubMed
Poly ADP-ribose polymerase inhibitors: science and current clinical development. Curr Opin Oncol. 2010 Nov; 22(6):567-72.
View in:
PubMed
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010 Mar 16; 17(3):298-310.
View in:
PubMed
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):401-6.
View in:
PubMed
Notch1 and Notch3 Overexpression in Young Women with Papillary Serous Ovarian Carcinoma. USCAP 97th Annual Meeting. 2008; Abst #1448.
The Metastasis-Associated Protein 1 (MTA1) is a Prognostic Biomarker in Papillary Serous Ovarian Carcinoma. USCAP 97th Annual Meeting. 2008; Abst #1447.
Epithelial Ovarian Cancer. 2007.
Protein expression and clinical features of ovarian cancer in the elderly. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1. 2007; 25(18S):5574.
ErbB3 protein expression in serous ovarian carcinomas of elderly women. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 1. 2007; 25(18S):16026.
Treatment of advanced ovarian cancer. Touch Briefings. 2006.
Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. J Natl Compr Canc Netw. 2006 Oct; 4(9):947-53.
View in:
PubMed
End-of-Life Care. Treatment and Management of Cancer in the Elderly. Ed: Hyman Muss, Carrie Hunter, Karen Johnson. 2006; 559-586.
Interns' work hours. N Engl J Med. 2005 Feb 17; 352(7):726-8; author reply 726-8.
View in:
PubMed
CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol. 2001 Oct; 19(4):791-8.
View in:
PubMed